NasdaqCM - Nasdaq Real Time Price USD

Accelerate Diagnostics, Inc. (AXDX)

0.9301 -0.0055 (-0.59%)
At close: April 26 at 4:00 PM EDT
Key Events
Loading Chart for AXDX
DELL
  • Previous Close 0.9356
  • Open 0.9200
  • Bid --
  • Ask --
  • Day's Range 0.8854 - 0.9450
  • 52 Week Range 0.7300 - 11.9000
  • Volume 4,924
  • Avg. Volume 72,770
  • Market Cap (intraday) 20.15M
  • Beta (5Y Monthly) 0.53
  • PE Ratio (TTM) --
  • EPS (TTM) -4.9400
  • Earnings Date May 9, 2024 - May 13, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 1.50

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

acceleratediagnostics.com

134

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AXDX

Performance Overview: AXDX

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AXDX
76.27%
S&P 500
6.92%

1-Year Return

AXDX
89.67%
S&P 500
25.26%

3-Year Return

AXDX
98.82%
S&P 500
22.00%

5-Year Return

AXDX
99.51%
S&P 500
74.29%

Compare To: AXDX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AXDX

Valuation Measures

Annual
As of 4/26/2024
  • Market Cap

    20.15M

  • Enterprise Value

    46.15M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.96

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    3.83

  • Enterprise Value/EBITDA

    -0.93

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -70.07%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    12.06M

  • Net Income Avi to Common (ttm)

    -61.62M

  • Diluted EPS (ttm)

    -4.9400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    13.22M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -25.94M

Research Analysis: AXDX

Company Insights: AXDX

Research Reports: AXDX

People Also Watch